Both the Hutchinson cancer center and Sloan Kettering have owned stock in Juno and are entitled Novartis substantial paymentsJuno —    up to $ 350 million and $ 150 million   —    if Juno ’s stock reaches certain levels .The N. I. H. does not take equity positions in companies to avoid an appearance of a conflict of interest .So to critics of the government deals , drug prices are crucial to understanding taxpayer value .